BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 29720585)

  • 1. De novo activating mutations drive clonal evolution and enhance clonal fitness in KMT2A-rearranged leukemia.
    Hyrenius-Wittsten A; Pilheden M; Sturesson H; Hansson J; Walsh MP; Song G; Kazi JU; Liu J; Ramakrishan R; Garcia-Ruiz C; Nance S; Gupta P; Zhang J; Rönnstrand L; Hultquist A; Downing JR; Lindkvist-Petersson K; Paulsson K; Järås M; Gruber TA; Ma J; Hagström-Andersson AK
    Nat Commun; 2018 May; 9(1):1770. PubMed ID: 29720585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23/
    Bill M; Mrózek K; Kohlschmidt J; Eisfeld AK; Walker CJ; Nicolet D; Papaioannou D; Blachly JS; Orwick S; Carroll AJ; Kolitz JE; Powell BL; Stone RM; de la Chapelle A; Byrd JC; Bloomfield CD
    Proc Natl Acad Sci U S A; 2020 Oct; 117(42):26340-26346. PubMed ID: 33020282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytogenetic and molecular genetic characterization of KMT2A-PTD positive acute myeloid leukemia in comparison to KMT2A-Rearranged acute myeloid leukemia.
    Vetro C; Haferlach T; Meggendorfer M; Stengel A; Jeromin S; Kern W; Haferlach C
    Cancer Genet; 2020 Jan; 240():15-22. PubMed ID: 31698332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flt3 does not play a critical role in murine myeloid leukemias induced by MLL fusion genes.
    Albouhair S; Morgado E; Lavau C
    PLoS One; 2013; 8(8):e72261. PubMed ID: 23977266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishment and characterization of a DOT1L inhibitor-sensitive human acute monocytic leukemia cell line YBT-5 with a novel KMT2A-MLLT3 fusion.
    Wang Z; Shi Y; Liu H; Liang Z; Zhu Q; Wang L; Tang B; Miao S; Ma N; Cen X; Ren H; Dong Y
    Hematol Oncol; 2019 Dec; 37(5):617-625. PubMed ID: 31701557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FLT3
    Hyrenius-Wittsten A; Pilheden M; Falqués-Costa A; Eriksson M; Sturesson H; Schneider P; Wander P; Garcia-Ruiz C; Liu J; Ågerstam H; Hultquist A; Lilljebjörn H; Stam RW; Järås M; Hagström-Andersson AK
    Leukemia; 2019 Sep; 33(9):2310-2314. PubMed ID: 30953031
    [No Abstract]   [Full Text] [Related]  

  • 7. Molecular characterization of KMT2A fusion partner genes in 13 cases of pediatric leukemia with complex or cryptic karyotypes.
    Ney Garcia DR; de Souza MT; de Figueiredo AF; Othman MAK; Rittscher K; Abdelhay E; Capela de Matos RR; Meyer C; Marschalek R; Land MGP; Liehr T; Ribeiro RC; Silva MLM
    Hematol Oncol; 2017 Dec; 35(4):760-768. PubMed ID: 27282883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia.
    Dafflon C; Craig VJ; Méreau H; Gräsel J; Schacher Engstler B; Hoffman G; Nigsch F; Gaulis S; Barys L; Ito M; Aguadé-Gorgorió J; Bornhauser B; Bourquin JP; Proske A; Stork-Fux C; Murakami M; Sellers WR; Hofmann F; Schwaller J; Tiedt R
    Leukemia; 2017 Jun; 31(6):1269-1277. PubMed ID: 27840424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First report of t(5;11) KMT2A-MAML1 fusion in de novo infant acute lymphoblastic leukemia.
    Tandon S; Shago M; Davidson S; Kanwar N; Fuligni F; Shlien A; Whitlock J; Villani A; Abla O
    Cancer Genet; 2020 Oct; 248-249():31-33. PubMed ID: 32992102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The RS4;11 cell line as a model for leukaemia with t(4;11)(q21;q23): Revised characterisation of cytogenetic features.
    Ragusa D; Makarov EM; Britten O; Moralli D; Green CM; Tosi S
    Cancer Rep (Hoboken); 2019 Oct; 2(5):e1207. PubMed ID: 32721124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of constitutive activation of FMS-related tyrosine kinase-3 and
    Fedders H; Alsadeq A; Schmäh J; Vogiatzi F; Zimmermann M; Möricke A; Lenk L; Stadt UZ; Horstmann MA; Pieters R; Schrappe M; Stanulla M; Cario G; Schewe DM
    Haematologica; 2017 Nov; 102(11):e438-e442. PubMed ID: 28838992
    [No Abstract]   [Full Text] [Related]  

  • 12. GAS6 Oncogene and Reverse MLLT3-KMT2A Duplications in an Infant with Acute Myeloid Leukemia and a Novel Complex Hyperdiploid Karyotype: Detailed High-Resolution Molecular Cytogenetic Studies.
    Capela de Matos RR; Ney Garcia DR; Cifoni E; Othman MAK; Tavares de Souza M; Carboni EK; Ferreira GM; Liehr T; Ribeiro RC; M Silva ML
    Cytogenet Genome Res; 2017; 152(1):33-37. PubMed ID: 28595195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a novel KMT2A-SEPT14 fusion in acute myeloid leukemia.
    Nguyen D; Haley L; Pallavajjala A; Gojo I; Ning Y
    Leuk Lymphoma; 2018 Jan; 59(1):265-267. PubMed ID: 28573893
    [No Abstract]   [Full Text] [Related]  

  • 14. Distinct Responses to Menin Inhibition and Synergy with DOT1L Inhibition in
    Adriaanse FRS; Schneider P; Arentsen-Peters STCJM; Fonseca AMND; Stutterheim J; Pieters R; Zwaan CM; Stam RW
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38892207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel KMT2A-USO1 fusion gene-induced de novo secondary acute myeloid leukaemia in a patient initially diagnosed with acute promyelocytic leukaemia.
    Jin W; Chen L; Liu Y; Chen Q; Zhao M; Tan Y; Zhang W; Song H; Weng X; Mi J; Chen S; Chen Z; Li J; Wang K
    Br J Haematol; 2021 Jan; 192(1):e32-e36. PubMed ID: 33216970
    [No Abstract]   [Full Text] [Related]  

  • 16. Recurrent
    Matsuo H; Yoshida K; Fukumura K; Nakatani K; Noguchi Y; Takasaki S; Noura M; Shiozawa Y; Shiraishi Y; Chiba K; Tanaka H; Okada A; Nannya Y; Takeda J; Ueno H; Shiba N; Yamato G; Handa H; Ono Y; Hiramoto N; Ishikawa T; Usuki K; Ishiyama K; Miyawaki S; Itonaga H; Miyazaki Y; Kawamura M; Yamaguchi H; Kiyokawa N; Tomizawa D; Taga T; Tawa A; Hayashi Y; Mano H; Miyano S; Kamikubo Y; Ogawa S; Adachi S
    Blood Adv; 2018 Nov; 2(21):2879-2889. PubMed ID: 30381403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KMT2A (MLL) rearrangements observed in pediatric/young adult T-lymphoblastic leukemia/lymphoma: A 10-year review from a single cytogenetic laboratory.
    Peterson JF; Baughn LB; Pearce KE; Williamson CM; Benevides Demasi JC; Olson RM; Goble TA; Meyer RG; Greipp PT; Ketterling RP
    Genes Chromosomes Cancer; 2018 Nov; 57(11):541-546. PubMed ID: 30203571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia.
    Chen CW; Koche RP; Sinha AU; Deshpande AJ; Zhu N; Eng R; Doench JG; Xu H; Chu SH; Qi J; Wang X; Delaney C; Bernt KM; Root DE; Hahn WC; Bradner JE; Armstrong SA
    Nat Med; 2015 Apr; 21(4):335-43. PubMed ID: 25822366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First case of B ALL with KMT2A-MAML2 rearrangement: a case report.
    Menu E; Beaufils N; Usseglio F; Balducci E; Lafage Pochitaloff M; Costello R; Gabert J
    BMC Cancer; 2017 May; 17(1):363. PubMed ID: 28535805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute myeloid leukemia with t(10;11)(p11-12;q23.3): Results of Russian Pediatric AML registration study.
    Zerkalenkova E; Lebedeva S; Kazakova A; Tsaur G; Starichkova Y; Timofeeva N; Soldatkina O; Aprelova E; Popov A; Ponomareva N; Baidun L; Meyer C; Novichkova G; Maschan M; Maschan A; Marschalek R; Olshanskaya Y
    Int J Lab Hematol; 2019 Apr; 41(2):287-292. PubMed ID: 30624859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.